CosmoFarm S.A., a wholly owned subsidiary of Cosmos Health Inc., delivered record revenue of over $15 million in the second quarter of 2026, representing an annualized run-rate of over $60 million. The subsidiary added more than 80 new pharmacies to its distribution network during the period, solidifying its position as a leading pharmaceutical wholesaler in the greater Athens area. To support this accelerating growth, Cosmos Health is increasing capital expenditure at CosmoFarm, investing in new robotic automation and artificial intelligence systems to enhance procurement, inventory management, and order fulfillment.

Expansion and Automation Investments

Cosmos Health is expanding the size of the CosmoFarm facility to accommodate higher volumes and continued network expansion. These investments build on CosmoFarm's existing automated infrastructure, including ROWA and SSI SCHÄFER A-frame robotic systems. The company stated that these systems have driven improvements in operational efficiency, unit economics, and profitability per customer.

Key Performance Indicators

Management Commentary

Greg Siokas, CEO of Cosmos Health, stated that CosmoFarm's record second quarter marks an important milestone, with revenue reaching an annualized run-rate of over $60 million. He noted that the addition of over 80 new pharmacies reflects the strength of the company's distribution platform and the trust of its growing customer base. Siokas further emphasized that by investing further in robotic automation, artificial intelligence, and expanded facility capacity, the company is positioning CosmoFarm to sustain this momentum, improve margins, and continue scaling profitably.

Cosmos Health Inc. has entered the global beauty and personal care market, launching a premium, Korean-developed collagen-based skincare line in the United States. The move targets the $163 billion global skincare market, which is projected to reach approximately $203 billion by 2033, according to Grand View Research. This strategic expansion aims to diversify the company's portfolio into higher-margin, high-growth categories.

Sales of the new brand have been live for over a month in the U.S., utilizing a direct-to-consumer model designed for global scale. Cosmos Health plans to roll out a series of products, pursuing a multi-brand strategy to deepen its presence in the skincare sector. The company stated that premium skincare is among the fastest-growing segments, driven by rising consumer demand for science-backed formulations.

Greg Siokas, CEO of Cosmos Health, emphasized that entering the beauty market is a natural extension of the company's strategy. He highlighted that the direct-to-consumer model and planned multi-brand portfolio are expected to contribute significantly to future growth. The launch marks a key step in the company's diversification toward more lucrative end markets.

Cosmos Health Inc. is a diversified, vertically integrated global healthcare group incorporated in 2009 in Nevada. The company owns proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, and bio-bebe®. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, and cosmetics within the European Union.

The company distributes pharmaceuticals and parapharmaceuticals to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Cosmos Health has also established R&D partnerships targeting major health disorders and entered the telehealth space via the acquisition of ZipDoctor, Inc. Its global distribution platform includes offices and distribution centers in Greece and the UK.